On June 18, the Centralized Procurement Office of Pharmaceuticals and Medical Devices of the Public Resources Trading Center of Guangxi Zhuang Autonomous Region issued the "Notice on Requesting Price Clarification of Questioned and Complained Varieties" (hereinafter referred to as the "Notice"), and suspended the disputed and complained varieties Online transaction qualifications. The attachment to the "Notice" shows that due to price issues, 363 drugs need to be clarified, and there are many large varieties.

clarify in time to regain eligibility

The "Notice" pointed out that the 2015 Guangxi drug bidding and procurement shortlisted varieties in the country's lowest three provinces shortlisted price announcements ended on June 3, 2019. During the public announcement period, 363 drugs were questioned and complained, and the products involved are now dealt with: the online trading qualifications of the questioned and complained products are suspended.

From the perspective of 363 drugs, many leading companies face doubts and complaints due to price reasons. For companies, price is the key to the competition of sourcing and procurement to enter the market, while the prices of large varieties from all over the country and the maintenance of the national price system are very important, and naturally they have become the core object of questioning.

After sorting out, the content that needs to be clarified for the questioned company's varieties is mainly focused on failing to truthfully fill in the lowest three-provincial price, not truthfully filling in the short-listed price of a certain province, not filling in the double-envelope short-listed price, omission of the price of a certain province, price inversion of the variety, and declaration of the lowest price Wrong etc.

Taking pemetrexed disodium for injection as an example, the product specification of Jiangsu Hausen with a specification of 0.2g, according to the minimum three-provincial price declaration requirements of the bidding procurement varieties, needs to fill in the winning bid price of the double-envelope bidding procurement. After inquiries, the company The reported prices in Heilongjiang and Jilin are directly linked to the Internet and do not meet the reporting requirements. However, Jiangsu Aosaikang Pharmaceutical of the same specification did not complete the double-envelope finalist price of 1,273.32 yuan/piece in Jilin and 1,296.83 yuan/piece in Shaanxi.

Several companies have also raised doubts about prices for multiple varieties. For example, Chia Tai Tianqing has a total of 7 drugs that have been questioned. Palonosetron Hydrochloride Injection 5ml: 0.25g incompletely filled in the double envelope. The shortlisted prices: Hunan 53.93 yuan/piece and Zhejiang 53.9 yuan/piece; Entecavir Dispersible Tablets 1.0 mg*7 unfinished double-envelope finalist price Shaanxi 157.34 yuan/box; capecitabine 0.5*12 unfinished double-envelope finalist price Sichuan and Jiangxi 91.2 yuan/box, Zhejiang 92.77 yuan/box, Jiangsu 94.5 yuan /Box, the price of 96 yuan/box in Henan; 0.3g*1 of Biapenem for injection, underreporting the price of 104.83 in Hunan...

The various specifications of clopidogrel bisulfate tablets 75mg*7 tablets, 25mg*20 tablets, 75m*10 tablets, 25mg*10 tablets of Lepu Pharmaceutical Co., Ltd. have all been questioned on the price. Among them, the lowest price of 75mg*7 tablets is the provincial and municipal price. It should be: Zhejiang 45.17, low-priced provinces and cities Ningxia 45.49, low-priced provinces and cities Jiangxi 45.6344; the lowest price of 25mg*20 tablets should be: Zhejiang 44.27, low-priced provinces and cities Ningxia 44.27, low-priced provinces and cities Hunan 44.74.

In addition, multinational pharmaceutical giants also have varieties involved. Roche's capecitabine tablets 0.5g*12, the price of 330 yuan/box in Sichuan, Hubei and Zhejiang for the double envelope shortlisted price was not fully filled in. AstraZeneca Omeprazole Magnesium Enteric-coated Tablets 20mg*7s, Guangxi Zhuang Autonomous Region Public Resources Trading Center announced the lowest three-province shortlisted prices on May 28, and it was found that the variety was a double-envelope public bidding procurement variety in Sichuan and won the bid The price is 72.93 yuan.

Although 363 drugs have been suspended from the Internet due to price issues, Guangxi also stated that from now on, manufacturers are requested to clarify in a timely manner according to the content listed in the annex. For the prices clarified by the manufacturers, the online trading of related varieties will be resumed after verification. qualifications.

Prices are gradually converging everywhere

Except for Guangxi, in the past two years, many provinces have adopted similar measures to obtain true and reasonable quotations for enterprise products. In the “Notice Concerning Submission of Clarification Materials Related to the Submission of the Minimum Bid-Winning (Internet) Price Declaration Information in the 5 Provinces (Autonomous Regions and Municipalities)” issued by Guangdong Pharmaceutical Exchange Center, a total of 332 drug prices were questioned.

From the perspective of the industry, it is not unusual for the same product to have different prices in different regions due to different recruitment policies. However, under the general trend of more and more transparent price information and more and more regions proposing "price linkage", if prices are too different or too high, they will inevitably raise questions.

There are also business people who believe that as prices become more transparent, especially under the influence of the "4+7" policy, it will test the company's own cost control and market strategies. At this stage, due to different regional policies, the biggest challenge for companies is how to make market choices. Because if the price is high in one place, the price is low in one place, and there is no synchronized price in the whole country, once the price is lowered, the national price will be linked again, which will affect the sales in all regions.

An expert once told reporters that since the previous price linkage was under the same common name, it is actually difficult to linkage the prices of products from different manufacturers, and linkage and inactivity is a common phenomenon. However, the current situation is slowly changing. In particular, with the advancement of generic drug consistency evaluation, a cross-regional market for high-quality manufacturers has gradually formed, and it has become feasible for high-quality manufacturers to form a national market, and price linkage has practical significance. In the context of the optimization and integration of the pharmaceutical market, the advancement of consistency evaluation will lead to the convergence of drug use across the country. What can be expected in the future is that once a company's products form a national market, the company will attach great importance to price protection strategies, and price differences in various regions will gradually disappear.